Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-03-28 Governance Information
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
关于拟变更经营范围并修订公司章程公告
Governance Information Classification · 95% confidence The document is a detailed announcement from 江苏森萱医药股份有限公司 regarding proposed amendments to the company's Articles of Association (公司章程) and changes to the business scope. It includes extensive legal and regulatory references, detailed provisions about shareholder meetings, board responsibilities, shareholding restrictions, and governance rules. The content is focused on corporate governance, company rules, and internal regulations rather than financial results, audit opinions, or shareholder meeting materials. There is no indication that this is a full annual report, audit report, earnings release, or a call transcript. The document is not a brief announcement or a report publication notice but a substantive governance-related document. Therefore, the most appropriate classification is Governance Information (CGR).
2022-03-28 Chinese
2021年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the 2021 annual profit distribution plan (权益分派预案公告) by Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the proposed cash dividend distribution per 10 shares, the total amount of dividends to be paid, and the approval process including board and independent directors' opinions. It references the 2021 annual report but does not contain the full annual report or detailed financial statements itself. The document is relatively short (2055 characters) and serves as a formal announcement of the dividend plan and related approvals, not the full annual report or financial statements. Therefore, it fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2022-03-28 Chinese
2021年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制自我评价报告' which translates to '2021 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control evaluation for the fiscal year ending December 31, 2021. The content includes detailed descriptions of internal control systems, evaluation scope, standards for identifying control deficiencies, and conclusions about the effectiveness of internal controls. It is a comprehensive report on internal control effectiveness rather than a general annual report or financial statement. This type of document aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and audit-related information rather than full financial performance or other categories. The document length (6396 characters) and detailed content support classification as AR rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-03-28 Chinese
独立董事关于第三届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various board meeting agenda items, including approval of reports on the use of raised funds, profit distribution plans, remuneration for senior management, cash management proposals, internal management system revisions, and the reappointment of the auditing firm. It is a formal announcement related to board meeting decisions and opinions rather than the full reports or financial statements themselves. The document length is short (2906 characters) and it mainly contains independent directors' opinions on board resolutions, which aligns with Board/Management Information filings. There is no detailed financial data or full report content, so it is not an Annual Report, Audit Report, or Interim Report. Therefore, the best classification is Board/Management Information (MANG).
2022-03-28 Chinese
2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2021. It contains detailed financial data including assets, liabilities, net profit, earnings per share, shareholder structure, and other comprehensive business and financial information. It also includes audit opinions and statements from company officers guaranteeing the accuracy of the report. The length of the document (6127 characters) and the detailed financial and operational data indicate this is the actual annual report or a substantial summary of it, not merely an announcement or a brief summary. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-03-28 Chinese
高级管理人员薪酬管理办法
Governance Information Classification · 95% confidence The document is titled '江苏森萱医药股份有限公司高级管理人员薪酬管理办法' which translates to 'Senior Management Compensation Management Measures' of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the company's internal policy on senior management compensation, including principles, salary composition, performance assessment, and payment methods. The document references the board of directors' approval and internal management rules, but it does not contain financial statements, earnings data, or regulatory filings. It is a governance-related document outlining internal rules and procedures for executive compensation. Therefore, it fits best under Governance Information (CGR). The document length is 2790 characters, which is relatively short but contains substantive policy content rather than just an announcement or certification. Hence, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2022-03-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.